(Press-News.org) A new, bio-inspired drug restores the effectiveness of immune cells in fighting cancer, a team led by researchers at The University of Texas at Austin has found. In mouse models of melanoma, bladder cancer, leukemia and colon cancer, the drug slows the growth of tumors, extends lifespan and boosts the efficacy of immunotherapy. The research is published in the journal Cancer Cell and could be a game changer for many cancer patients.
Many cancers delete a stretch of DNA called 9p21, which is the most common deletion across all cancers, occurring in 25%-50% of certain cancers such as melanoma, bladder cancer, mesothelioma and some brain cancers. Scientists have long known that cancers with the 9p21 deletion mean worse outcomes for patients and resistance to immunotherapies — the treatment strategies designed to supercharge a patient’s natural immune response to cancer.
The deletion helps cancer cells avoid getting detected and wiped out by the immune system, in part by prompting the cancer to pump out a toxic compound called MTA that impairs normal functioning of immune cells and also blocks the effectiveness of immunotherapies.
“In animal models, our drug lowers MTA back down to normal, and the immune system comes back on,” said Everett Stone, a research associate professor in the Department of Molecular Biosciences and associate professor of oncology at Dell Medical School, who led the work. “We see a lot more T cells around the tumor, and they’re in attack mode. T cells are an important immune cell type, like a SWAT team that can recognize tumor cells and pump them full of enzymes that chew up the tumor from the inside out.”
Stone envisions the drug being used in combination with immunotherapies to boost their effectiveness.
The study’s co-first authors are Donjeta Gjuka, a former UT postdoctoral researcher and currently a scientist at Takeda Oncology, and Elio Adib, formerly a postdoctoral researcher at Brigham and Women’s Hospital and the Dana-Farber Cancer Institute, and currently a resident physician at Mass General Brigham.
The 9p21 deletion leads to the loss of some key genes in cancer cells. Gone are a pair of genes that produce cell cycle regulators — proteins that keep healthy cells growing and dividing at a slow, steady rate. When those genes are lost, cells can grow unchecked. That’s what makes them cancerous. Also deleted is a housekeeping gene that produces an enzyme that breaks down the toxin MTA. It’s this loss, according to Stone, that lets cancer cells acquire a new superpower: the ability to deactivate the immune system.
“Cancer gets a two-for-one when it loses both of these genes,” Stone said. “It loses the brakes that normally keep it from growing in an uncontrolled manner. And then at the same time, it disarms the body’s police force. So, it becomes a much more aggressive and malignant kind of cancer.”
To create their drug candidate, Stone and his colleagues started with the helpful enzyme that’s naturally produced by the body to break down MTA and then added flexible polymers.
“It’s already a really good enzyme, but we needed to optimize it to last longer in the body,” Stone said. “If we injected just the natural enzyme, it would be eliminated within a few hours. In mice, our modified version stays in circulation for days; in humans it will last even longer.”
The researchers plan to do more safety tests on their drug, called PEG-MTAP, and are seeking funding to take it into human clinical trials.
The study’s other co-authors from UT are Kendra Garrison, Candice Lamb, Yuri Tanno and George Georgiou. The study’s co-corresponding authors are Stone and David Kwiatkowski, a senior physician at Brigham and Women's Hospital and a professor of medicine at Harvard Medical School.
This work was supported by funding from the National Cancer Institute, the Doris Duke Foundation, The University of Texas MD Anderson Cancer Center, the Joan and Herb Kelleher Charitable Foundation, the Kidney Cancer Association, the V Foundation and the U.S. Department of Defense.
The University of Texas at Austin is committed to transparency and disclosure of all potential conflicts of interest. University investigators involved in this research have submitted required financial disclosure forms with the University. Stone and Gjuka are inventors of two patents related to this work owned by The University of Texas at Austin.
END
Cancer drug restores immune system’s ability to fight tumors
Drug candidate is effective in mice with cancers of skin, bladder, blood and colon
2023-10-09
ELSE PRESS RELEASES FROM THIS DATE:
Newfound mechanism suggests drug combination could starve pancreatic cancer
2023-10-09
A new combination of treatments safely decreased growth of pancreatic cancer in mice by preventing cancer cells from scavenging for fuel, a new study finds.
Led by researchers at NYU Grossman School of Medicine, its Department of Radiation Oncology, and the Perlmutter Cancer Center, the work builds on prior discoveries at NYU Langone that revealed how pancreatic cancer cells, to avert starvation and keep growing, find alternate fuel sources. Normally supplied by the bloodstream, oxygen, blood sugar, and other resources become scarce as the increasing density of fast-growing pancreatic tumors cuts off their own blood supply. ...
Epigenetic regulator MOF drives mitochondrial metabolism
2023-10-09
The intricate control of cellular metabolism relies on the coordinated and harmonious interplay between the nucleus and mitochondria. On the one hand, mitochondria are the hub for the production of essential metabolites, which aside from being required to meet the energy demands of the cell, also serve as the building blocks for constructing both genetic and epigenetic landscapes in the nucleus. On the other hand, the majority of mitochondrial metabolic enzymes are encoded by the nuclear genome, making the function of these two organelles highly interdependent on one another. Inter-organellar communication is aided by molecules that shuttle between these two compartments. ...
Do you know a stroke hero?
2023-10-09
Each year, approximately 800,000 people in the U.S. experience a stroke, according to the American Heart Association’s 2023 Heart Disease and Stroke Statistical Update. Individuals and groups making a difference in the stroke community have a chance to be nationally recognized with a 2024 Stroke Hero Award from the American Stroke Association, a division of the American Heart Association, which is devoted to a world of healthier lives for all.
Stroke is the fifth leading cause of death and a leading cause of serious, long-term ...
UofL receives $16 million to increase supply of primary care physicians for underserved rural and urban areas
2023-10-09
The University of Louisville has received $16 million to help increase Kentuckians’ access to health care, particularly in underserved rural and urban areas. The UofL School of Medicine will use the funds from a four-year grant from the Health Resources and Services Administration (HRSA) to train more primary care physicians and encourage them to practice in underserved communities where they are needed.
Kentucky has a severe shortage of health care providers, with at least some portion of 113 of the state’s 120 counties designated as Health Professional Shortage Areas, including ...
TAVR: Less than one-third of patients enter cardiac rehab after heart procedure
2023-10-09
The vast majority of people who have a minimally invasive heart valve replacement procedure do not participate in recommended cardiac rehabilitation, a Michigan Medicine-led study finds.
Researchers used clinical registry and health care claims data from over 3,300 patients who underwent transcatheter aortic valve replacement, or TAVR, in Michigan across 24 hospitals between 2016 and mid-2020, to determine the rate of cardiac rehabilitation participation and the factors associated with its utilization.
Results published in JACC: Advances reveal that just 30.6% ...
Newly-discovered “margarita snails” from the Florida Keys are bright lemon-yellow
2023-10-09
The “Margaritaville” in Jimmy Buffett’s famous song isn’t a real place, but it’s long been associated with the Florida Keys. This string of tropical islands is home to the only living coral barrier reef in the continental US, along with many animals found nowhere else in the world. One of them is a newly-discovered, bright yellow snail, named in honor of Margaritaville. The lemon- (or, key-lime-) colored snail, along with its lime-green cousin from Belize, is the subject of a study published in the journal PeerJ.
These marine snails are distant relatives of the land-dwelling gastropods you ...
McLean Hospital collaborates with Rippl Care to address urgent mental health needs of seniors living with dementia and their family caregivers
2023-10-09
To address a crisis of unmet mental health needs among seniors with dementia and their family caregivers amid a shortage of mental health providers with expertise treating this population, McLean Hospital, a member of Mass General Brigham, has entered into an agreement to offer strategic advisory services and professional education to Rippl Care. Rippl provides specialty dementia care and is pioneering a new care model in an effort to expand access to high quality, wraparound behavioral healthcare for seniors, their families and caregivers. Under McLean’s agreement with Rippl Care, leaders in the ...
Heart disease risk, prevention and management redefined
2023-10-09
Advisory Highlights:
A new American Heart Association presidential advisory identifies the strong connections among cardiovascular disease (CVD), kidney disease, Type 2 diabetes and obesity, and suggests redefining CVD risk, prevention and management.
The advisory defines cardiovascular-kidney-metabolic (CKM) syndrome for the first time.
CKM syndrome ranges from Stage 0, or no risk factors and an entirely preventive focus, to Stage 4, the highest-risk stage with cardiovascular disease. Stage 4 may also include kidney failure.
The advisory urges use of a new tool that will predict someone’s likelihood of heart attack, stroke and/or heart failure ...
Clinical trial demonstrates benefits of solriamfetol for adults with ADHD
2023-10-09
BOSTON – Although several medications are approved to treat attention-deficit/hyperactivity disorder (ADHD), some individuals experience limited benefits from the drugs or develop side effects from their use. A recent clinical trial published in the Journal of Clinical Psychiatry by investigators at Massachusetts General Hospital (MGH), a founding member of Mass General Brigham (MGB), has demonstrated that the drug solriamfetol may be an effective alternative for managing ADHD in adults.
Solriamfetol is currently approved in the United States for ...
Tropical ecosystems more reliant on emerging aquatic insects, study finds, potentially putting them at greater risk
2023-10-09
A team of researchers from Queen Mary University of London and the University of Campinas in Brazil has found that tropical forest ecosystems are more reliant on aquatic insects than temperate forest ecosystems and are therefore more vulnerable to disruptions to the links between land and water.
The study, published in the journal Ecology Letters, is the first to directly compare the interconnections between land and water in tropical and temperate environments via the emergence of aquatic insects. The researchers used a technique called stable isotope analysis to trace ...
LAST 30 PRESS RELEASES:
Insulin resistance is linked to over 30 diseases – and to early death in women, study of people in the UK finds
Innovative semaglutide hydrogel could reduce diabetes shots to once a month
Weight loss could reduce the risk of severe infections in people with diabetes, UK research suggests
Long-term exposure to air pollution and a lack of green space increases the risk of hospitalization for respiratory conditions
Better cardiovascular health in early pregnancy may offset high genetic risk
Artificial intelligence method transforms gene mutation prediction in lung cancer: DeepGEM data releases at IASLC 2024 World Conference on Lung Cancer
Antibody–drug conjugate I-DXd shows clinically meaningful response in patients with extensive-stage small cell lung cancer
IASLC Global Survey on biomarker testing reveals progress and persistent barriers in lung cancer biomarker testing
Research shows pathway to developing predictive biomarkers for immune checkpoint inhibitors
Just how dangerous is Great Salt Lake dust? New research looks for clues
Maroulas appointed Associate Vice Chancellor, Director of AI Tennessee
New chickadee research finds cognitive skills impact lifespan
Cognitive behavioral therapy enhances brain circuits to relieve depression
Terasaki Institute awarded $2.3 Million grant from NIH for organ transplantation research using organs-on-a-chip technology
Atoms on the edge
Postdoc takes multipronged approach to muon detection
Mathematical proof: Five satellites needed for precise navigation
Scalable, multi-functional device lays groundwork for advanced quantum applications
Falling for financial scams? It may signal early Alzheimer’s disease
Integrating MRI and OCT for new insights into brain microstructure
Designing a normative neuroimaging library to support diagnosis of traumatic brain injury
Department of Energy announces $68 million in funding for artificial intelligence for scientific research
DOE, ORNL announce opportunity to define future of high-performance computing
Molecular simulations, supercomputing lead to energy-saving biomaterials breakthrough
Low-impact yoga and exercise found to help older women manage urinary incontinence
Genetic studies reveal new insights into cognitive impairment in schizophrenia
Researcher develops technology to provide cleaner energy and cleaner water
Expect the unexpected: nanoscale silver unveils intrinsic self-healing abilities
nTIDE September 2024 Jobs Report: Gains in employment for people with disabilities appear to level off after reducing gaps with non-disabled workers
Wiley enhances NMR Spectral Library Collection with extensive new databases
[Press-News.org] Cancer drug restores immune system’s ability to fight tumorsDrug candidate is effective in mice with cancers of skin, bladder, blood and colon